



Fascin in Cancer, from Prognostic Marker to Molecular Target

Guest Editor:

Prof. Dr. Pablo Conesa-Zamora

Molecular Pathology and
Pharmacogenetic Group
(Institute for Biomedicine
Research from Murcia (IMIB)),
Spain

Deadline for manuscript
submissions:
closed (15 September 2021)

Message from the Guest Editor

Dear Colleagues,

Metastasis is the cause of over 90% of deaths due to cancer. In order for the tumor cell to acquire an invasive and metastatic phenotype, specific cytoskeleton rearrangements are needed which mainly involve actin. Fascin is the key protein in actin bundling, which a crucial process for generation of invasive structures such as lamellipodia and invadopodia. Moreover, fascin contributes to metastasis by altering mitochondrial function and metabolic stress resistance. Not surprisingly, fascin overexpression is associated with tumors with aggressive behavior, high metastatic potential, and resistance to chemotherapy, and in most cases, available targeted therapies are lacking. Recent X-ray crystal structures of fascin bound to chemical compounds have opened the possibility for specific drugs designed to target this protein which plays a causative role in tumor progression. This Special Issue will cover the different functions of fascin in tumor development and promotion, its value as prognostic marker in cancer, and promising advances in the design of chemical compounds targeting this actin-bundling protein.

Prof. Dr. Pablo Conesa-Zamora
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)